MARTINSRIED, Germany, Nov. 10, 2008 (GLOBE NEWSWIRE) -- MorphoSys AG (Frankfurt:MOR) (Prime Standard Segment, TecDAX) announced today that its management will give company presentations at two investor conferences in November 2008.
Dr. Simon Moroney, Chief Executive Officer of MorphoSys AG, will present at the Rodman & Renshaw 10th Annual Healthcare Conference, being held November 10-12 in New York City, USA.
Dave Lemus, Chief Financial Officer of MorphoSys AG, will present at the German Equity Forum 2008, being held November 10-12 in Frankfurt, Germany.
Rodman & Renshaw 10th Annual Healthcare Conference Date: Tuesday, November 11, 2008 Time: 2:25 p.m. ET (8:25 p.m. CET; 7:25 p.m. GMT) Venue: The New York Palace Hotel, New York, USA German Equity Forum 2008 Date: Tuesday, November 11, 2008 Time: 12:00 CET (6:00 a.m. ET; 11:00 a.m. GMT) Venue: Congress Center and Hall 5.1, Frankfurt Messe, Frankfurt, Germany
Live and archived webcasts of the presentations will be available at www.morphosys.com.
About MorphoSys:
MorphoSys is a publicly traded biotechnology company focused on the generation of fully human antibodies as a means to discover and develop innovative antibody-based drugs against life-threatening diseases. MorphoSys's goal is to establish HuCAL as the technology of choice for antibody generation in research, diagnostics and therapeutic applications. The Company currently has therapeutic and research alliances with the majority of the world's largest pharmaceutical companies including Boehringer Ingelheim, Centocor/Johnson & Johnson, Novartis, Pfizer and Roche. Within these partnerships, more than 50 therapeutic antibody programs are ongoing in which MorphoSys participates through exclusive license and milestones payments as well as royalties on any end products. Additionally, MorphoSys is active in the antibody research market through its AbD Serotec business unit. The business unit has operations in Germany (Munich), the U.S. (Raleigh, NC) and U.K.(Oxford). For further information please visit http://www.morphosys.com/
HuCAL and HuCAL GOLD are registered trademarks of MorphoSys AG
This communication contains certain forward-looking statements concerning the MorphoSys group of companies. The forward-looking statements contained herein represent the judgment of MorphoSys as of the date of this release and involve risks and uncertainties. Should actual conditions differ from the Company's assumptions, actual results and actions may differ from those anticipated. MorphoSys does not intend to update any of these forward-looking statements as far as the wording of the relevant press release is concerned.
This announcement was originally distributed by Hugin. The issuer is solely responsible for the content of this announcement.